Brokers Offer Predictions for Stryker Corporation’s Q1 2018 Earnings (SYK)

Stryker Corporation (NYSE:SYK) – Stock analysts at William Blair lifted their Q1 2018 earnings estimates for shares of Stryker Corporation in a research note issued to investors on Thursday. William Blair analyst K. Krum now anticipates that the medical technology company will post earnings of $1.55 per share for the quarter, up from their previous estimate of $1.54. William Blair also issued estimates for Stryker Corporation’s Q2 2018 earnings at $1.69 EPS.

Stryker Corporation (NYSE:SYK) last posted its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.39 earnings per share. COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for Stryker Corporation’s Q1 2018 Earnings (SYK)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/01/brokers-offer-predictions-for-stryker-corporations-q1-2018-earnings-syk.html.

Other research analysts have also recently issued research reports about the stock. Wells Fargo & Company lifted their target price on shares of Stryker Corporation from $160.00 to $166.00 in a research note on Friday, October 27th. Cowen and Company restated a “buy” rating and set a $160.00 target price (up previously from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Stifel Nicolaus lifted their target price on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a research note on Monday, July 17th. Finally, BidaskClub upgraded shares of Stryker Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $151.52.

Stryker Corporation (NYSE SYK) traded down 0.22% on Monday, hitting $154.53. 741,884 shares of the stock traded hands. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $160.62. The company’s 50 day moving average price is $146.25 and its 200-day moving average price is $142.26. The stock has a market cap of $57.80 billion, a price-to-earnings ratio of 34.49 and a beta of 0.80.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th were issued a $0.425 dividend. The ex-dividend date was Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.10%. Stryker Corporation’s dividend payout ratio (DPR) is presently 36.32%.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the transaction, the insider now directly owns 88,207 shares in the company, valued at approximately $12,909,976.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Graham A. Mclean sold 1,124 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.

A number of large investors have recently modified their holdings of SYK. Raymond James Financial Services Advisors Inc. grew its holdings in Stryker Corporation by 1.9% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 167,998 shares of the medical technology company’s stock valued at $22,118,000 after purchasing an additional 3,187 shares during the last quarter. Northstar Wealth Partners LLC bought a new position in Stryker Corporation during the 1st quarter valued at about $206,000. Mason Street Advisors LLC grew its holdings in Stryker Corporation by 0.6% during the 1st quarter. Mason Street Advisors LLC now owns 42,769 shares of the medical technology company’s stock valued at $5,631,000 after purchasing an additional 254 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Stryker Corporation by 1.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 120,140 shares of the medical technology company’s stock valued at $15,816,000 after purchasing an additional 1,857 shares during the last quarter. Finally, Pacer Advisors Inc. grew its holdings in Stryker Corporation by 3.3% during the 1st quarter. Pacer Advisors Inc. now owns 6,799 shares of the medical technology company’s stock valued at $895,000 after purchasing an additional 216 shares during the last quarter. Institutional investors own 74.00% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply